Abeona Therapeutics has reported significant commercial progress for its gene therapy, ZevaSkin, designed to treat recessive dystrophic epidermolysis bullosa (RDEB). Since its launch in late 2025, the company has treated two patients and biopsied three more, with plans to expand treatment through four activated Qualified Treatment Centers (QTCs). Demand has surged, with the eligible patient pool now exceeding 100, driven by outreach to community physicians.
The financial implications are noteworthy, as Abeona’s total revenue for 2025 reached $5.8 million, bolstered by a $1.524 billion gain from the sale of a priority review voucher. The establishment of a permanent HCPCS J-code for ZevaSkin enhances billing clarity and may facilitate quicker patient access. As the company ramps up operations, it anticipates improved gross margins and revenue normalization as the payer mix diversifies beyond Medicaid.
Investors should monitor Abeona’s progress in scaling ZevaSkin treatments and expanding QTCs, which could significantly impact future revenue growth. For a deeper dive into Abeona’s operational updates and financial results, I recommend checking out the full article.
Source: fool.com